Weight-loss injections like Mounjaro and Wegovy produce rapid weight regain four times faster than traditional dieting once patients stop treatment, according to recent research published in the British Medical Journal. People using these medications shed approximately one-fifth of their body weight, but upon discontinuing treatment, they regain roughly 0.8 kilograms monthly on average, returning to their original weight within approximately 18 months.
The research analyzed 37 studies involving over 9,000 patients comparing injectable weight-loss medications with conventional dieting approaches and other pharmaceutical interventions. However, only eight studies examined the newer GLP-1 medications such as Wegovy and Mounjaro, with maximum follow-up periods of one year after medication cessation, meaning these projections represent estimates rather than confirmed data.
Those pursuing traditional dieting experience slower weight rebound, approximately 0.1 kilograms monthly, though this varies considerably among individuals. Dr Susan Jebb from Oxford University emphasizes that prospective users must understand the substantial risk of rapid weight regain when treatment concludes, noting that extended research into long-term effects would prove beneficial for treatment planning.
The mechanism behind accelerated weight rebound involves how these medications affect appetite regulation in the brain and body. The injections mimic GLP-1, a naturally occurring hormone controlling hunger signals. Prolonged artificial elevation of GLP-1 levels may reduce the body’s natural hormone production and diminish sensitivity to it, leaving individuals vulnerable to intense appetite and overeating upon treatment cessation, according to nutrition expert Dr Adam Collins from the University of Surrey.
Approximately 1.6 million UK adults have used these injections within the past year, predominantly through private prescriptions rather than NHS provision. An additional 3.3 million adults express interest in using these medications within the coming year, representing roughly one in ten UK adults having either tried or wishing to try injectable weight-loss treatments. Usage patterns demonstrate twice the prevalence among women compared to men, with higher adoption rates among individuals in their 40s and 50s.
Medical guidelines recommend these injections exclusively for individuals with obesity and related health complications, not for cosmetic weight reduction. Treatment should incorporate lifestyle modifications including dietary improvements and regular physical activity to sustain weight loss long-term. Many medical professionals advocate viewing such treatment as potentially lifelong given the substantial relapse risk once discontinuation occurs.
The NHS currently imposes no specified duration limits for Mounjaro prescriptions, whereas Wegovy authorization extends to a maximum of two years. Some researchers suggest that maintaining treatment for three to four years enables sustained weight reduction exceeding typical lifestyle-induced weight loss outcomes, where substantial weight regain frequently occurs over time.
